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Hepatitis C virus (HCV) is a global health issue. Although direct-acting antivirals are 
available to target HCV, there is currently no vaccine. The diversity of the virus is a major 
obstacle to HCV vaccine development. One approach toward a vaccine is to utilize a 
strategy to elicit broadly neutralizing antibodies (bNAbs) that target highly-conserved 
epitopes. The conserved epitopes of bNAbs have been mapped almost exclusively to 
the E2 glycoprotein. In this study, we have used HCV-GLUE, a bioinformatics resource 
for HCV sequence data, to investigate the major epitopes targeted by well-characterized 
bNAbs. Here, we analyze the level of conservation of each epitope by genotype and 
subtype and consider the most promising bNAbs identified to date for further study as 
potential vaccine leads. For the most conserved epitopes, we also identify the most 
prevalent sequence variants in the circulating HCV population. We examine the distribu-
tion of E2 sequence data from across the globe and highlight regions with no coverage. 
Genotype 1 is the most prevalent genotype worldwide, but in many regions, it is not the 
dominant genotype. We find that the sequence conservation data is very encouraging; 
several bNAbs have a high level of conservation across all genotypes suggesting that 
it may be unnecessary to tailor vaccines according to the geographical distribution of 
genotypes.
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inTrODUcTiOn
Hepatitis C virus (HCV), a member of the Flaviviridae family, is a major cause of liver disease 
worldwide. Recent estimates indicate that HCV infects approximately 71 million people globally 
(1). Approximately 70% of infected individuals develop a chronic infection that can lead to liver 
cirrhosis and hepatocellular carcinoma (HCC). Termed a “silent killer,” the initial infection is usu-
ally asymptomatic and individuals are often unaware that they carry the infection until symptoms 
develop several decades later. In recent years, a number of effective direct-acting antiviral (DAA) 
drugs have been developed. However, the silent nature of initial infection makes timely diagnosis 
and treatment more challenging. The long period of chronic infection may already have caused 
irreversible liver damage or initiated a chain of events that will ultimately result in HCC even if the 
virus is successfully cleared by DAA-treatment post-diagnosis (2, 3). Further studies are required 
to address this question. This and other factors including cost, access to treatment, and reinfection 
enforces the pressing need for a prophylactic vaccine for HCV.
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One of the major barriers to vaccine development for HCV 
is the sequence diversity of the virus. Currently, there are seven 
genotypes and 67 subtypes that have at least 33 or 15% nucleotide 
variation, respectively (4). As a result, an effective vaccine must 
be capable of protecting against challenge by an extremely diverse 
viral population. The question is how to design such a vaccine? 
HCV has two surface glycoproteins E1 and E2 that form a heter-
odimer. These proteins govern the entry process of the virus. The 
E2 glycoprotein, which contains the receptor-binding site (RBS) 
for the cellular receptors CD81 and SR-BI is the most studied 
(5, 6). E2 contains a number of variable regions; hypervariable 
region 1 (HVR1) is located at the N-terminus (aa384-427), this 
region has been shown to be important for interaction with the 
SR-BI receptor and to play a role in antibody evasion by shielding 
epitopes and preventing neutralization (7–12). The roles of the 
other variable regions are less defined, they are hypervariable 
region 2 (aa461-481) and the intergenotypic variable region 
(aa570-580) (8, 13). E2 has ~11 N-linked glycosylation sites that 
form a glycan shield, which has also been shown to be involved 
in immune evasion (14). An insight into possible targets for HCV 
vaccine development, i.e., surface-exposed, conserved regions of 
the HCV glycoproteins can be gleaned from studies into broadly 
neutralizing antibodies (bNAbs). Viral neutralizing antibodies 
have been shown to inhibit infection by either blocking interac-
tion with the RBS or by inhibition of the post-entry fusion mecha-
nism (15, 16). By definition, bNAbs do this by targeting highly 
conserved regions within the viral glycoproteins that are involved 
in these processes. We generated the HCV bNAb, AP33 in 2001 
and demonstrated in 2005, with the development of the HCV 
pseudoparticle (HCVpp) system that it was able to neutralize par-
ticles decorated with diverse HCV E1E2 glycoproteins (17, 18). 
Since then, there has been significant progress in the isolation 
and characterization of HCV bNAbs, as reviewed by Ball et al. 
(19). The majority of HCV bNAbs have been shown to target the 
E2 glycoprotein particularly the CD81 RBS. Within the literature, 
several different nomenclatures are used to describe these regions, 
herein, we will use Epitopes 1–4 (20, 21). The potential of utilizing 
HCV bNAbs to inform rational vaccine design and the associated 
challenges has been the topic of recent reviews (22, 23). With the 
plethora of HCV bNAbs now available, which of these would 
be the most promising for further analysis and vaccine design? 
In this study, we have probed a large HCV sequence dataset to 
determine the level of conservation of each bNAb epitope. Using 
this data and documented neutralization studies, we conclude 
that the most promising candidates to date as a starting point for 
development of a bNAb-based vaccine approach are HC84.20, 
AR4A, 1:7, A8 and AP33. 95-2, HCV1, and Hu5B3.v3 also have 
strong potential, but there are insufficient neutralization data 
available at this time.
MaTerials anD MeThODs
epitope identification
For each bNAb, the epitope reported in the literature cited 
was used. For the majority of bNAbs, this was straightforward; 
however, for a small group, the data in different publications 
were conflicting. We have used an eight-residue binding motif 
for bNAb AR3C that differs from the original epitope identified 
by alanine-scanning (24). These eight residues were consistent 
between two subsequent reports; the crystal structure of AR3C 
bound to core E2 and also in an extensive alanine-scanning 
study (25, 26). AR3A, AR3B, and AR3D were excluded from 
our analysis as the alanine-scanning data were conflicting and 
no structural data were available to corroborate either study. We 
have also updated the binding motifs of several conformational 
bNAbs (HC84.20, HC84.24, HC84.26, HC-1, HC-11) reported by 
the Foung lab to incorporate a later study by Pierce and cowork-
ers that includes a comprehensive E1E2 alanine-scanning study 
(27). Residues that inhibited binding by at least 80% were selected 
as critical-binding residues. Crucially, as these antibodies bind 
conformational epitopes, alanine mutation may alter the overall 
structure of E1E2; therefore, mutations in regions that affected 
binding of all conformational antibodies were not included.
Bioinformatic analysis
The analysis of public HCV sequence data was performed within 
Genes Linked by Underlying Evolution (GLUE) (28). GLUE is 
an open source, data-centric bioinformatics environment special-
ized for the analysis of virus genomic sequence data.
GLUE was used to create a public sequence data resource 
called HCV-GLUE (28) for the study of HCV genomes. HCV-
GLUE provides an interactive web application for public use; the 
underlying dataset may be also downloaded to a local computer. 
This dataset currently contains approximately 92,000 HCV 
sequences derived from the public GenBank database (29) and 
is updated on a daily basis. Sequences from non-human hosts, 
<500 bases in length, recombinant, or patent-related are excluded 
from the set. Within HCV-GLUE, each sequence is assigned a 
genotype and where possible a subtype according to a maximum 
likelihood method based on the scheme proposed by Smith et al. 
(4). Furthermore, each sequence is maintained in alignment to 
a closely related reference sequence. The GLUE software system 
provides basic functions for the analysis of amino acid residues 
across sets of stored sequences. A residue numbering scheme 
proposed by Kuiken et al. (30) is used within HCV-GLUE.
GLUE allows existing projects such as HCV-GLUE to be 
extended to address-specific research questions. For the cur-
rent article, we created an extension, HCV-NABS, which may 
be downloaded from https://github.com/giffordlabcvr/HCV-
NABS. The HCV-NABS extension augments the HCV-GLUE 
dataset with data relating to 38 neutralizing antibodies and their 
putative-binding locations. We then also created scripts within 
the HCV-NABS extension to analyze the frequency of amino 
acid residue patterns both at individual binding locations and 
at combinations of binding locations pertaining to each bNAb. 
Procedures were also added to report the numbers of sequences 
within each genotype containing a substantial part (90%) of the 
E2 region of the HCV genome. These data were stratified accord-
ing to the country of origin, which had been annotated in the 
GenBank record, if any. We used the HCV-GLUE characterization 
of sequence genotypes and subtypes to stratify the analysis. The 
bioinformatics analysis may be reproduced by installing GLUE, 
HCV-GLUE, and the HCV-NABS extension on any computer.
TaBle 1 | Broadly neutralizing antibodies and their epitopes analyzed in the study.
name e2-binding residues region targeted identification of residues reference
AR4A Y201, T204, N205, D206, R657, L692, D698 E1E2 Mutagenesis (32)
AR5A Y201, T204, N205, D206, R639, R657 E1E2 Mutagenesis (32)
J6.36 F403, G406 Hypervariable region 1 (HVR1) Mutagenesis (33)
J6.103 F403, G406 HVR1 Mutagenesis (33)
H77.16 G406, N410, I411 HVR1 Mutagenesis (33)
HC33.4 K408, L413, W420 HVR1, Epitope 1 Mutagenesis (34)
HC33.8 K408, L413, G418, W420 HVR1, Epitope 1 Mutagenesis (34)
HC33.29 K408, L413, G418, W420 HVR1, Epitope 1 Mutagenesis (34)
AP33 L413, N415, G418, W420 Epitope 1 Structure (17, 35, 36)
Hu5B3.v3 L413, N417, W420, I422 Epitope 1 Structure (37)
HC33.1 L413, G418, W420 Epitope 1 Structure (34, 38)
HC33.32 L413, G418, W420 Epitope 1 Mutagenesis (34)
HCV1 L413, N415, G418, W420 Epitope 1 Structure (39, 40)
95-2 L413, W420 Epitope 1 Mutagenesis (39)
H77.39 N415, N417 Epitope 1 Mutagenesis (33)
3/11 N415, W420, H421 Epitope 1 Structure (41–43)
Mab24 T416, G418, W420, H421 Epitope 1 Mutagenesis (44)
HC84.22 W420, N428, C429, W437, L441, F442, Y443, W616 Epitope 1, 2, and 4 Mutagenesis (27, 45)
HC84.23 W420, N428, C429, W437, L441, F442, Y443, W616 Epitope 1, 2, and 4 Mutagenesis (27, 45)
AR3C T425, N428, C429, L438, L441, F442, Y443,W529 Epitope 2 and 3 Structure (24–26)
e20 T425, L427, N428, W437, F442, W529, G530, D535, W616 Epitope 2 and 3 Mutagenesis (46–48)
HC-11 T425, N428, C429, G436, W437, L438, F442, Y443, D520, G530, D535 Epitope 2 and 3 Mutagenesis (27, 49)
HC-1 C429, W529, G530, D535 Epitope 3 Mutagenesis (49, 50)
HC84.20 C429, L441, Y613, W616 Epitope 2 and 4 Mutagenesis (27, 34)
HC84.21 C429, L441, F442, Y443 Epitope 2 Mutagenesis (27, 34)
HC84.24 C429, F442, Y443 Epitope 2 Mutagenesis (27, 34)
HC84.25 C429, L441, F442, W616 Epitope 2 and 4 Mutagenesis (27, 34)
HC84.27 C429, L441, F442, Y443, K446, W616 Epitope 2 and 4 Structure (27, 34, 51)
mAb#8 W437, L438 Epitope 2 Structure (52, 53)
mAb#41 W437, L438 Epitope 2 Peptide mapping (52)
CBH-2 W437, A439, G530, D535 Epitope 2 and 3 Mutagenesis (49)
HC84.1 L441, F442 Epitope 2 Structure (34, 51)
HC84.26 L441, F442 Epitope 2 Mutagenesis (34)
1:7 G523, T526, Y527, W529, G530, D535 Epitope 3 Mutagenesis (54)
A8 G523, T526, Y527, W529, G530, D535 Epitope 3 Mutagenesis (54)
MAb44 G523, P525, N540, W549, Y613 Epitope 3 and 4 Mutagenesis (44)
J6.27 A524, W529 Epitope 3 Mutagenesis (33)
H77.31 W529, G530, D533 Epitope 3 Mutagenesis (33)
aItalicized residues are not in Epitopes 1–4. Numbering is according to the H77 polyprotein. Antibodies are listed in numerical order according to the first residue of their epitope.
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resUlTs
identification of the bnab epitopes
A group of 38 monoclonal antibodies that has been shown to have 
broad neutralization activity were selected from the literature. 
Importantly, the epitopes of this group of antibodies have been 
characterized by alanine-scanning mutagenesis and/or structural 
analysis. The bNAbs have been isolated and characterized by many 
different groups. However, often several antibodies were isolated 
from the same source as indicated by the nomenclature. The largest 
such group is the HC84 group; these are all designated as HC84.
xx and tend to share overlapping epitopes. The bNAbs used in this 
study are shown in Table 1, together with the region of E1E2 that 
they target and the specific residues that are critical for antibody 
binding. It is well documented that most neutralizing antibodies 
target particular regions of the E2 glycoprotein that are involved 
in CD81 binding; Epitope 1 (aa412–423), Epitope 2 (aa434–446), 
Epitope 3 (aa523–535), and Epitope 4 (aa611–617) as shown in 
Figure 1 (20, 21). We compared the specific residues bound by all 38 
bNAbs and identified 47 E1E2 residues, 27 of which lie within these 
four epitopes. Certain residues seem to be key target residues as 
they are recognized by several bNAbs from different sources these 
include; W420 in Epitope 1 and F442 in Epitope 2 that are targeted 
by 12 and 11 bNAbs, respectively (Figure 2). We have shown that 
W420 is a critical residue modulating interactions with the cellular 
receptors CD81 and SR-BI (31). Other residues only form part 
of the epitope for 1 bNAb, for instance, T416, A439, and D533.
analysis of the level of conservation  
of bnab Target residues
Rather than focusing on the designated epitope regions, we 
determined the level of conservation of all 47 residues recog-
nized by HCV bNAbs, as a significant number of the antibody-
interacting residues are outside these regions (refer to Table  1 
for details). We used the HCV-GLUE to analyze the level of 
conservation for each genotype (1–7) and 10 subtypes (Figure 3; 
Table S1 in Supplementary Material). For the majority of bNAbs 
FigUre 2 | Relative usage of residues bound by broadly neutralizing antibodies. The graph plots the number of broadly neutralizing antibodies in this study that use 
each amino-acid as part of their epitope.
FigUre 1 | Regions of E2 targeted by broadly neutralizing antibodies. (a) Epitope 1 (412–423) is flexible. The structure of this region has been solved bound to 
several broadly neutralizing antibodies. In AP33 (blue) (PDB 4GAG) and HCV1 (green) (PDB 4DGV), this region forms a β-hairpin structure. In HC33.1 (red) (PDB 
4XVJ), it has an intermediate structure between a β-hairpin and a coil and in 3/11 (purple) (PDB 4WHT), it has an extended conformation. (B) The core E2 structure 
(PDB 4MWF) with Epitope 2 (434–446) in magenta, Epitope 3 (525–535) in cyan, and Epitope 4 (611–617) in blue.
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alanine-scanning mutagenesis in the genotype (gt), 1a H77 strain 
was used to determine the bNAb antibody-interacting residues. 
The J6 group of bNAbs is the exception as this was mapped using 
the gt2a J6 virus strain. Consequently, in our analysis, we used 
the sequence that was used to map the antibody interaction as the 
reference sequence. Predictably, the overall level of conservation 
among these residues, which are bound by bNAbs, was high. 
Positions 408K, 410N in HVR1 and 411I just downstream were 
less well conserved. In Epitope 1, threonine at position 416 is 
substituted by serine in a large proportion of gt2a, gt2c, gt3b, and 
gt4a. In Epitopes 2 and 3, two residues 437W and 533D were well-
conserved for gt1 and gt1a but were found to be preferentially 
replaced by a similar residue, phenylalanine, and glutamic acid, 
respectively, in all other genotypes and subtypes. Likewise, at 
position 438, the leucine residue found in the H77 gt1a sequence 
was an isoleucine in the majority of sequences. Some variants 
were very genotype specific. In gt2, position 446K was gener-
ally serine, arginine, or asparagine depending on the particular 
subtype. The majority of gt3 and gt6 sequences have a glutamic 
acid residue replacing the asparagine at position 540; however, 
in the subtype gt3b, this is commonly a threonine residue. Both 
variants are particularly interesting as substitution of N540 
removes a potential N-linked glycosylation motif at this position.
The number of amino-acid variants identified (excluding 
that of the reference sequence), for each position is shown in 
Figure 4. Generally, gt1 has a greater range of variants for each 
position, although this may be skewed due to the large number 
of gt1 sequences (>23,000) in the database compared to the other 
genotypes. Even so, it is clear from the data that certain positions 
are less tolerant of variation than others, most notably residues 
within E1 (201–206) and toward the E2 C-terminal end (613, 639, 
692, 698). Interestingly, of the other six positions whereby nearly 
all the genotypes/subtypes have fewer than three variants namely 
406, 413, 421, 436, 523, 526, three of these are glycine residues.
analysis of the level of conservation  
of bnab epitopes
To assess how well the complete binding motif of each bNAb 
was conserved, we determined the residue with the lowest 
FigUre 3 | Conservation of bNAb-bound residues. The level of conservation (%) with respect to the reference sequence is shown for each genotype and subtype. 
Gt1 (red), Gt2 (green), Gt3 (purple), Gt4 (blue), Gt5 (yellow), Gt6 (pink), and Gt7 (teal).
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level of conservation relative to the reference sequence for each 
motif (refer to Table 2). There is the possibility that a particular 
residue may be differentially conserved between genotypes and 
therefore, this was done for all seven genotypes. These values were 
combined to give the % conservation for all genotypes for each 
binding motif, and this figure was used to rank the bNAb panel 
from the most conserved overall (HC84.20) to the least conserved 
(mAb#8, mAb#41 and HC-11). The number of genotypes where 
the binding motif was conserved by at least 90% is also reported 
in Table 2. Epitopes of six antibodies had this level of conserva-
tion in all seven genotypes. In contrast, the epitope residues of 
15 antibodies did not reach this degree of conservation in the 
glycoprotein of any genotype. The level of conservation varied 
with respect to each genotype. The epitopes of gt4 E1E2 had the 
highest level of conservation, with 22/38 antibodies displaying 
>90% conservation of their binding motifs. This compares to only 
7/38 antibodies in the case of gt3, suggesting that this genotype 
may be the most difficult to neutralize with this bNAb panel.
The epitopes of antibodies AR4A and AR5A, which bind 
residues in E1 and toward the C-terminus of E2, were highly 
conserved. Epitope 1 is also well-conserved, indeed, the majority 
of bNAbs that target this region are ranked highly overall. The dif-
ferences in rank, of the Epitope 1-binding bNAbs, can be attrib-
uted to the specific residues recognized by each antibody. For 
FigUre 4 | Variance of bNAb bound residues. The number of different amino-acid variants for each residue is shown across the different genotypes and subtypes. 
Gt1 (red), Gt2 (green), Gt3 (purple), Gt4 (blue), Gt5 (yellow), Gt6 (pink) and Gt7 (teal).
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instance, bNAbs AP33, HCV1, H77.39, and 3/11 all bind N415, 
which has a lower level of conservation in gt2, gt3, and gt5. This 
reduces the level of conservation of these antibodies compared 
to HC33.1, 95-2 or Hu5B3.v3, which do not require N415 for 
binding. Similarly, the Mab24 epitope is not as well conserved due 
to its requirement for T416. For the HC33 group of antibodies, 
those that require K408 are ranked lower overall as this residue, 
which is located in the HVR1, perhaps unsurprisingly, is poorly 
conserved. However, in contrast, the residues 403 and 406 in 
HVR1 that are recognized by J6.36 and J6.103 are unexpectedly 
well-conserved (>90% conservation in gt4, gt5, and gt6).
The bNAbs that bind to Epitope 2 generally perform less well, 
the exception is HC84.20, which ranked at the top of Table 2. Many 
of the HC84 series of the bNAbs are the highest ranking Epitope 
2-interacting antibodies. There is >90% conservation of the bind-
ing motif within this region of E2 of gt2, gt4, and gt6, whereas 
the corresponding residues in the gt1 and gt3 glycoproteins are 
less conserved (81.85 and 74.83%, respectively). This is even more 
TaBle 2 | The lowest conservation (%) for each bNAb epitope binding motif across genotypes.
















no. gt >90% region targeted rank
AR4A 99.79 99.78 99.72 99.15 99.65 99.86 100 697.95 7 E1E2 2
AR5A 99.79 99.78 99.8 99.15 99.65 99.65 100 697.82 7 E1E2 3
J6.36 85.02 85.28 81.48 92.85 92.76 91.93 0 529.32 3 Hypervariable region 1 (HVR1) 21=
J6.103 85.02 85.28 81.48 92.85 92.76 91.93 0 529.32 3 HVR1 21=
H77.16 59.4 39.75 4.8 18.6 2.72 25.16 0 150.43 0 HVR1 29
HC33.4 36.58 33.51 21.96 16.88 29.53 49.3 0 187.76 0 HVR1, Epitope 1 25=
HC33.8 36.58 33.51 21.96 16.88 29.53 49.3 0 187.76 0 HVR1, Epitope 1 25=
HC33.29 36.58 33.51 21.96 16.88 29.53 49.3 0 187.76 0 HVR1, Epitope 1 25=
AP33 97.57 72.57 86.88 94.94 85.82 95.62 100 633.4 4 Epitope 1 11=
Hu5B3.v3 96.05 97.19 97.24 98.05 96.30 88.03 100 672.86 6 Epitope 1 8
HC33.1 99.66 99.56 99.85 99.87 97.06 99.83 100 695.83 7 Epitope 1 5=
HC33.32 99.66 99.56 99.85 99.87 97.06 99.83 100 695.83 7 Epitope 1 5=
HCV1 97.57 72.57 86.88 94.94 85.82 95.62 100 633.4 4 Epitope 1 11=
95-2 99.73 99.56 99.9 100 97.06 99.83 100 696.08 7 Epitope 1 4
H77.39 97.57 72.57 86.88 94.94 85.82 95.62 100 633.4 4 Epitope 1 11=
3/11 97.57 72.57 86.88 94.94 85.82 95.62 100 633.4 4 Epitope 1 11=
Mab24 91.08 63.21 84.21 85.73 86.67 80.96 100 591.86 2 Epitope 1 15
HC84.22 59.59 4.2 0 0.92 0 0.51 0 65.22 0 Epitope 1, 2, and 4 32=
HC84.23 59.59 4.2 0 0.92 0 0.51 0 65.22 0 Epitope 1, 2, and 4 32=
AR3C 42.23 28.13 15.14 46.2 7.69 13.59 0 152.98 0 Epitope 2 and 3 28
e20 59.59 4.2 0 0.92 0 0.51 0 65.22 0 Epitope 2, 3, and 4 32=
HC-11 42.23 4.2 0 0.92 0 0.51 0 47.86 0 Epitope 2 and 3 36=
HC-1 99.78 98.49 86.15 99.15 100 98.62 100 682.19 5 Epitope 3 7
HC84.20 99.81 99.58 99.8 99.51 100 100 100 698.7 4 Epitope 2 and 4 1
HC84.21 81.85 99.12 74.83 96.08 20.51 90.47 100 562.86 4 Epitope 2 16=
HC84.24 81.85 99.12 74.83 96.08 20.51 90.47 100 562.86 4 Epitope 2 16=
HC84.25 81.85 99.12 74.83 96.08 20.51 90.47 100 562.86 4 Epitope 2 and 4 16=
HC84.27 69.80 16.37 74.83 85.60 20.51 66.97 0 334.08 0 Epitope 2 and 4 24
mAb#8 42.23 4.2 0 0.92 0 0.51 0 47.86 0 Epitope 2 36=
mAb#41 42.23 4.2 0 0.92 0 0.51 0 47.86 0 Epitope 2 36=
CBH-2 59.59 4.2 0 0.92 0 0.51 0 65.22 0 Epitope 2 and 3 32=
HC84.1 81.85 99.12 74.83 96.08 20.51 90.47 100 562.86 4 Epitope 2 16=
HC84.26 81.85 99.12 74.83 96.08 20.51 90.47 100 562.86 4 Epitope 2 16=
1:7 95.81 98.49 86.15 97.86 94.74 98.62 100 671.67 6 Epitope 3 9=
A8 95.81 98.49 86.15 97.86 94.74 98.62 100 671.67 6 Epitope 3 9=
Mab44 98.73 99.43 4.03 99.51 100 0.56 100 502.26 5 Epitope 3 and 4 23
J6.27 61.23 25.14 38.41 1.26 0 4.52 0 130.56 0 Epitope 3 30
H77.31 49.09 3.02 2.12 9.83 10.53 1.4 0 75.99 0 Epitope 3 31
Shading denotes >90% conservation. Each antibody has been ranked from the most to the least conserved according to the sum of the lowest level of conservation (%) across all 
genotypes. An = symbol shows broadly neutralizing antibodies that have equivalent rank.
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striking in gt5 where conservation of the binding motif is only 
20.51%. These reductions are attributable to the phenylalanine 
at position 442 of the binding motif; this hydrophobic residue 
is changed to an aliphatic residue in a significant proportion of 
sequences. The particular aliphatic residue varies depending on 
genotype, e.g., leucine (12.38%) in gt1, isoleucine (18.6%) in gt3, 
and methionine (35.9%) in gt5. This change is likely to affect 
antibody binding. HC84.20 ranks so highly because F442 is not a 
critical binding residue for this bNAb. The HC84.22 and HC84.23 
binding motifs are poorly conserved, due to their interaction with 
W437. This residue also forms part of the binding motif for other 
bNAbs that interact with Epitope 2, CBH-2, mAb#8, mAb#41, 
and e20. However, in the majority of instances (>95% for all but 
gt1), it is replaced by the hydrophobic phenylalanine residue: this 
amino acid has very similar properties; therefore, it is likely that 
a degree of antibody binding would be retained. Remarkably, the 
binding motif of the strongly neutralizing bNAb AR3C has a low 
level of conservation across all genotypes. Further inspection of 
the sequences shows that this is due to L438, which is replaced by 
an isoleucine in the majority of sequences. This is a conservative 
change; therefore, it is probable that antibody interaction may be 
retained.






















HC84.20 98.58 99.73 98.48 99.72 100 99.79 99.75 99.24 100 100 Epitope 2 and 4
AR4A 99.76 99.57 99.8 99.7 100 99.74 98.13 98.13 99.23 100 E1E2
AR5A 99.76 99.57 99.8 99.7 100 99.76 100 98.13 99.23 100 E1E2
95-2 99.66 99.83 100 98.7 100 99.91 99.75 100 100 99.7 Epitope 1
HC33.1 99.55 99.83 100 98.7 100 99.82 99.75 100 99.82 99.7 Epitope 1
HC33.32 99.55 99.83 100 98.7 100 99.82 99.75 100 99.82 99.7 Epitope 1
HC-1 99.78 99.66 92.21 99.72 98.44 99.09 0 99.38 100 100 Epitope 2 and 3
1:7 94.62 98.87 92.21 99.43 98.44 99.09 0 97.5 100 100 Epitope 3
A8 94.62 98.87 92.21 99.43 98.44 99.09 0 97.5 100 100 Epitope 3
Hu5B3.v3 94.46 98.44 93.49 98.7 96.93 96.86 99.51 98.77 99.45 98.81 Epitope 1
AP33 96.98 98.49 97.27 82.94 39.47 84.85 97.8 100 93.91 95.87 Epitope 1
HCV1 96.98 98.49 97.27 82.94 39.47 84.85 97.8 100 93.91 95.87 Epitope 1
H77.39 96.98 98.49 97.27 82.94 39.47 84.85 97.8 100 93.91 95.87 Epitope 1
3/11 96.98 98.49 97.27 82.94 39.47 84.85 97.8 100 93.91 95.87 Epitope 1
Shading denotes > 90% conservation.
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investigation of bnab epitopes  
in hcV subtypes
The bNAbs with the most conserved binding motifs were further 
analyzed for the level of conservation at the HCV subtype level. 
For the analysis, we selected the 10 best represented subtypes in 
the dataset (1a, 1b, 2a, 2b, 2c, 3a, 3b, 4a, 4d, and 6a). This scrutiny 
revealed some interesting observations at the subtype level, as 
shown in Table 3. Surprisingly, the conservation of the binding 
motif of bNAbs HC-1, 1:7 and A8 was 0% in the 3b subtype 
compared to 99.09% for gt3a indicating that these antibodies 
may not neutralize gt3b. Further examination of the epitope 
sequence showed that this is due to replacement of W529 to a 
phenylalanine in all gt3b sequences (n = 351) in the database. 
This is a relatively conservative change from one hydrophobic 
residue to another; therefore, it is probable that the bNAbs will 
still bind gt3b. Likewise, further dissection of the genotypes into 
subtypes for the Epitope 1-binding bNAbs AP33, HCV1, H77.39 
and 3/11 highlighted differences at the subtype level for both gt2 
and gt3. This is due to the asparagine residue at position 415. 
While in gt2a, there is a high level of conservation at this position 
(97.27%), this drops to 82.94% in gt2b and more substantially 
to only 39.47% in gt2c. While in gt2b, this drop is due to an 
increase in the presence of serine at this position, the major-
ity of gt2c sequences (57.68%) were found to have a histidine 
residue instead. Serine and asparagine are both hydrophilic, 
neutral residues and therefore this change may not substantially 
affect antibody binding. Histidine, however, is positively charged 
and this more dramatic change, found in gt2c, is more likely to 
abrogate antibody interaction. Similarly, in gt3a, there is a drop 
in conservation of N415 to 86.88%. This decrease is due to a 
higher prevalence of the positively charged arginine residue at 
this position, which would also be predicted to inhibit antibody 
binding.
analysis of the Binding Motif Pattern
The conservation analysis reported above treats each position 
within the antibody motif as a single entity. This approach 
would not identify changes within the binding motif pattern 
that modify more than one substitution within the epitope. To 
investigate this, we analyzed the complete binding motif pattern 
for the 10 bNAbs with the most conserved epitopes (Table 4; 
Table S2 in Supplementary Material). The most prevalent 
amino-acid patterns, i.e., found in at least 10 sequences are 
shown in Table 4. These data confirm the high level of conser-
vation of these epitopes across all seven genotypes. In all but 
one example, the most prevalent sequences only had a single 
substitution within the binding motif. For bNAbs AR4A and 
AR5A, the level of epitope conservation is particularly dramatic. 
From over 9,700 sequences analyzed, there was only a single 
alternative sequence that was present in at least 10 sequences. 
This had a single conservative change at E1 204 replacing 
threonine with serine. The HC84.20 epitope motif was also very 
highly conserved with a single alternative sequence present in 
1.1% of gt1 sequences.
The bNAb-binding motifs in Epitope 1 bound by 95/2 and 
HC33.1 and HC33.32 were marginally more variable; however, 
each alternative sequence was still represented at a low frequency 
(fewer than 50 copies) in the database. There was more sequence 
variation across the Hu5B3.v3-binding motif in Epitope 1, with 
12 different sequences identified. For all the Epitope 1-interacting 
bNAbs, there was no obvious preference for mutations at specific 
positions as substitutions were found to occur at all residues in 
the bNAb epitopes and all but one sequence was reported in at 
least two genotypes. Similarly, in Epitope 3 where the HC-1, 1:7, 
and A8 binding motifs share three common residues (W529, 
G530 and D535), there was no pattern for which residue in 
the binding motif was altered. Gt3 sequences had the lowest 
frequency of conservation, due to the substitution of W529 with 
a phenylalanine residue.
geographical Distribution
Our analysis is based on the sequence data available in Genbank. 
To investigate how the available data reflected the global distribu-
tion of HCV, we analyzed the country of origin of the deposited 
sequences. We focused on E2 as this is the principal target 
of bNAbs; however, the data for both E1 and E2 are shown in 
TaBle 4 | The most prevalent sequences for the complete bNAb epitope motifs.
bnab sequence Percentage of sequences (%) Total no. sequences gt range
gt1 gt2 gt3 gt4 gt5 gt6 gt7
HC84.20 C/L/Y/W 98.6 99.2 99.5 99.5 100 100 100 11,379 1–7
C/L/H/W 1.10 0 0 0 0 0 0 89 1
AR4A Y/TND/R/L/D 99.3 99.2 99.2 97.5 100 99.6 100 9,704 1–7
Y/SND/R/L/D 0.11 0 0 1.97 0 0 0 12 1, 4
AR5A Y/TND/R/R 99.5 99.5 99.4 97.5 100 99.1 100 9,741 1–7
Y/SND/R/R 0.11 0 0 1.97 0 0 0 12 1, 4
95/2 L/W 99.6 99.6 99.9 100 96.3 99.7 100 29,658 1–7
L/R 0.15 0.07 0.05 0 0 0.17 0 39 1, 2, 3, 6
P/W 0.07 0 0.05 0 0 0 0 19 1, 3
L/a 0.05 0.07 0 0 0 0 0 12 1, 2
L/C 0.04 0 0 0 0.75 0 0 11 1, 5
HC33.1 and HC33.32 L/G/W 99.3 99.3 99.7 99.9 94.8 99.5 100 29,565 1–7
L/N/W 0.19 0 0.03 0 0 0 0 45 1,3
L/G/R 0.15 0.07 0.05 0 0 0.17 0 39 1, 2, 3, 6
L/D/W 0.07 0 0.10 0 0 0 0 21 1, 3
P/G/W 0.07 0 0.05 0 0 0 0 19 1, 3
L/S/W 0.05 0.07 0 0 0.75 0.17 0 15 1, 2, 5, 6
L/G/a 0.05 0.07 0 0 0 0 0 12 1, 2
L/G/C 0.04 0 0 0 0.75 0 0 11 1, 5
HC-1 C/WG/D 99.4 98.1 85.7 98.3 100 98.6 100 13,764 1–7
C/FG/D 0.04 0 13.4 0.43 0 1.08 0 380 1, 3, 4, 6
C/WG/G 0.12 0 0 0 0 0 0 12 1
C/RG/D 0.07 0 0.11 0 0 0 0 10 1, 3
1:7 and A8 G/TY/WG/D 91.9 97.5 82.9 96.6 94.7 97.2 100 12,806 1–7
G/TF/WG/D 3.64 0 2.6 2.14 0 1.10 0 453 1, 3, 4, 6
G/TY/FG/D 0.02 0 13.4 0.43 0 1.10 0 377 1, 3, 4, 6
G/AY/WG/D 3.33 0.19 0 0 0 0 0 341 1, 2
G/TH/WG/D 0.37 0.19 0.07 0 0 0 0 41 1, 2, 3
G/TY/WG/G 0.11 0 0 0 0 0 0 11 1
Hu5B3.v3 L/N/W/I 95.0 96.1 96.1 97.7 92.5 87.0 100 27,806 1–7
L/N/W/L 2.37 0.07 0.03 0.65 0 0.51 0 555 1, 2, 3, 4, 6
L/N/W/V 1.40 2.59 2.70 1.30 0 11.3 0 537 1, 2, 3, 4, 6
L/S/W/I 0.40 0.37 0.23 0 0.75 0.34 0 109 1, 2, 3, 5, 6
L/D/W/I 0.16 0.15 0.05 0 0 0.17 0 42 1, 2, 3, 6
L/N/R/I 0.13 0.07 0.05 0 0 0.17 0 35 1, 2, 3, 6
L/Q/W/I 0 0 0.62 0 1.50 0 0 26 3, 5
L/N/W/T 0.10 0.07 0.05 0 0 0 0 25 1, 2, 3
P/N/W/I 0.07 0 0.05 0 0 0 0 15 1, 3
L/R/W/I 0.05 0 0 0 0 0 0 12 1
L/N/a/I 0.05 0.07 0 0 0 0 0 12 1, 2
L/N/C/I 0.04 0 0 0 0.75 0 0 11 1, 5
aSignifies a stop codon, sequence differences are shown in bold.
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Table S3 in Supplementary Material. The number of sequences 
that cover at least 90% of E2 for gt1–6 per country is shown 
in Figure  5. Genotype 7 is not shown as there are only two 
sequences, both of which were isolated in Canada. There are an 
additional 1,320 sequences representing gt1–6 where no country 
is specified. Even for gt1, the most prevalent genotype, while the 
USA is well-represented, large areas of the globe have severely 
limited or no sequence information for this region of the HCV 
genome. Indeed, there are no sequences for Central America, the 
Middle East, most of the African continent, Eastern Europe, and 
South America. This trend is even more pronounced with regard 
to the less prevalent genotypes. There are approximately 3,000 
more E1 sequences available compared to E2; however, the overall 
trend with respect to the global distribution is similar (Figure S1 
in Supplementary Material).
DiscUssiOn
The development of the GLUE software has enabled rapid analy-
sis of large datasets of viral sequences (28). HCV-GLUE is the 
most advanced project; however, similar data resources for other 
viruses including HIV and HBV are under development (R. 
Gifford and J. Singer, personal communication). In this study, 
we have assessed the level of conservation of the critical residues 
of HCV glycoproteins that are recognized by a panel of HCV 
bNAbs using HCV-GLUE. This analysis has identified a group of 
FigUre 5 | Global distribution of E2 sequence coverage. The maps are color-coded to show the number of E2 sequences (with at least 90% coverage) per country 
for Gt1 (red), Gt2 (green), Gt3 (purple), Gt4 (blue), Gt5 (yellow), and Gt6 (orange). Countries shaded in gray have no sequences reported.
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bNAbs that theoretically, based on epitope conservation, would 
be the best leads for a vaccine design strategy. However the 
presence of the epitope sequence is not the only factor dictating 
the efficacy of an antibody; the affinity of the antibody for its 
target is also important. We and others have noted that some 
isolates of E1E2 are more resistant to neutralization either by 
patient sera or purified bNAbs (12, 55–58). Indeed, two of these 
studies, which both performed large-scale neutralization stud-
ies of >80 E1E2 isolates identified three groups, with those that 
were either highly sensitive or highly resistant at the extremes 
and the majority falling somewhere in between. The reason 
for this is unclear, Urbanowicz and coworkers suggest that 
multiple mechanisms are likely to be involved as they could not 
identify any common sequence substitutions that explained the 
extreme phenotypes (55). In contrast, El-Diwany and coworkers 
demonstrated that two polymorphisms at positions 403 and 438 
modulate neutralization phenotype and suggest that this is via 
alteration of binding to the receptor SR-BI (57). Moreover, in 
the context of an HCV infection, it has been demonstrated that 
the glycan shield formed by extensive glycosylations of E1E2 can 
prevent bNAbs binding to their neutralizing epitopes (14, 59). 
Studies also indicate that the HVR1 of E2 functions to block 
access to neutralizing epitopes, this is variable between E1E2 
isolates strongly influencing the neutralization phenotype (12). 
Also relevant in the case of HCV, which is particularly diverse 
in sequence, is the possibility that a contributing factor to the 
breadth of binding by bNAbs may be due to the antibody para-
tope being able to accommodate alternative residues. Therefore, 
we examined the available neutralization data for the bNAbs 
with the most conserved epitopes.
By definition, all bNAbs can neutralize more than one viral 
genotype, although they have been assessed by different groups 
in different systems with different isolates and methods and thus 
it is difficult to compare the results directly. With regards to 
the conservation of the epitope sequence, we identify HC84.20 
as the top candidate; it has been assessed for neutralization 
activity in the HCV cell culture (HCVcc) system and was able 
to neutralize all E1E2 sequences (gt1–6) except for gt3. AR4A, 
which ranked second overall performed better in neutraliza-
tion studies reported by Giang et  al. (32). AR4A was able to 
neutralize the full complement of E1E2 sequences (gt1–6) tested 
in both the HCVpp and HCVcc systems. The AR4A epitope 
was conserved in all 24 sequences tested. AR4A was able to 
neutralize 85.8% of E1E2 isolate in a large-scale neutralization 
study (57). According to our data, as the AR5A epitope is also 
conserved in all the sequences tested, it should behave similarly. 
In practice; however, this bNAb could neutralize gt 2 sequences 
in the HCVcc system but not in the HCVpp system and could 
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not neutralize any gt3 sequence tested (32). From the alanine-
scanning mutagenesis, AR4A and AR5A have overlapping 
epitopes; however, our results together with the neutralization 
data suggest that AR5A binds additional residues that have 
yet to be identified (32). This is supported by the observation 
in the original paper that the epitope of AR5A but not AR4A 
overlaps with the epitope of the bNAb CBH-7 (32). CBH-7 was 
not included in our analysis as, despite much effort, the epitope 
has not yet been defined (27, 60, 61).
Several of the top-ranking bNAbs bind to Epitope 1; of these, 
bNAb 95-2 has the most conserved epitope composed of only two 
residues L413 and W420. This antibody was isolated by Broering 
and coworkers along with bNAb HCV1 (39). They report that both 
antibodies were able to neutralize all six HCVpp tested (gt 1–4) 
suggesting broad neutralization, although HCV1 was marginally 
less effective. There are no data available for gt 5 or 6. The fact 
that only two residues (L413 and W420) are required by bNAb 
95-2 for binding contributes to the high level of conservation. 
It should be noted that, in the original study, bNAb HCV1 was 
also reported to only require the same two residues. Subsequent 
work by Kong et  al. (40) who showed by alanine-scanning 
mutagenesis, and more importantly, by co-crystallization of 
HCV1 in complex with Epitope 1 peptide that N415 and G418 
were also required (40). To our knowledge, no further work with 
95-2 has been reported in the literature and therefore it remains 
possible that 95-2 may also require additional residues for bind-
ing. Other Epitope 1 bNAbs HC33.1, HC33.32, and H77.39 do 
not neutralize as well as we would predict from our results even 
though their epitopes are conserved in all the sequences tested 
(33, 34). Contrary to our predictions, in practice, H77.39 is the 
most effective, neutralizing gt1, gt2, gt4, and gt5 but not gt3 or 
gt6. HC33.1 did not efficiently neutralize gt2, gt3, or gt6 and 
HC33.32 performed marginally less well neutralizing only gt2, 
gt4, and gt5 (33, 34). These data suggest that other factors are 
influencing antibody performance. As mentioned above, these 
may be attributes of the antibody themselves such as affinity and 
avidity. Alternatively, properties of the E1E2 glycoproteins such 
as glycosylation or HVR1 structure may be preventing access to 
the epitope. Hu5B3.v3 could neutralize both gt1 and gt2, but it 
has not been tested against other genotypes (46).
AP33 and 3/11 that both recognize E2 Epitope 1 residues 
(L413, N415, G418, W420 for AP33 and N415, W420, H421 for 
3/11) have been tested against a wider range of E1E2 sequences 
although these studies were performed prior to the develop-
ment of the HCVcc system (18, 41). Tarr et  al. compared the 
performance of both antibodies in parallel (41). AP33 performed 
significantly better than 3/11, neutralizing 17/18 HCVpp (gt 1–6) 
compared to 6/18 isolates (gt1, gt2, gt4, gt5, and gt6). This is 
despite the 3/11 epitope being completely conserved, in con-
trast to that of AP33. Indeed, the sequence that AP33 did not 
neutralize contained two mutations in the AP33 epitope N415Q 
and G418S, which explains the lack of neutralization. Notably, 
a sequence that was neutralized by AP33 had a change in one 
of the antibody-interacting residues whereby N415 was replaced 
by a histidine. This is particularly interesting as nearly 60% of 
gt2c sequences have a histidine at this position. Therefore, this 
data suggests that AP33 can still bind and neutralize sequences 
containing this variant, which would increase the predicted 
level of AP33 binding to gt2 sequences. It has been shown that a 
mutation N417S/T results in a glycan shift within Epitope 1 from 
417 to 415 that can block binding with neutralizing antibodies, 
such as AP33, which require N415 (37, 62). The shift is due to a 
change in position 417 to either serine or threonine that creates 
an N-linked glycosylation site. Consequently, we checked the 
frequency of these mutations in the database. We find that these 
mutations have been detected in the majority of genotypes, with 
the exception of gt4 and gt7, albeit at low frequency (0.23–0.74%). 
AP33 performed well in a large-scale neutralization study with a 
mean IC50 value of 0.69 µg/ml (55). Hu5B3.v3 has been shown to 
neutralize gt1 and gt2 sequences, but there is no data for other 
genotypes (37).
The Epitope 3-binding antibodies 1:7 and A8 both have been 
shown to perform well in neutralization studies. They were 
tested against 10 different E1E2 sequences (gt1–6) in the HCVpp 
system (54). The epitope was conserved in all the sequences. 1:7 
was marginally better than A8 neutralizing HCVpp bearing all 
10 sequences by at least 50%. A8 only neutralized 9/10 isolates 
by >50%; however, this was at a relatively low concentration 
(15  µg/ml) compared to other studies. 1:7 was included in a 
large-scale neutralization study and shown to have a mean IC50 
value of 2.1 µg/ml (55). HC-1, which binds in part to Epitope 
3 did not function as well in neutralization tests. Although its 
epitope is conserved, HC-1 only neutralized 3/8 E1E2 sequences 
(gt1 and gt 5) tested (63). Similarly to bNabs 1:7 and A8, the 
highest concentration tested was 20 µg/ml compared to 50 µg/ml 
for other studies; therefore, this might improve at higher con-
centrations. From our bioinformatics analysis, the top bNAbs 
would be HC84.20, AR4A, AR5A, and 95/2; however, if we take 
into account the available neutralization data we can conclude 
that HC84.20, AR4A, 1:7, A8, and AP33 are the most promising 
lead candidates to date. 95-2, HCV1, and Hu5B3.v3 performed 
well in our analysis but have not been tested as extensively 
across different genotypes for neutralization. AR5A, HC33.1, 
HC33.32, HC-1, H77.39, and 3/11 all have highly conserved 
epitopes; however, they were not as effective in neutralization 
studies.
One unexpected result from our analysis was the relatively 
low level of conservation of the AR3C antibody epitope resi-
dues, this was principally due to the requirement for L438. This 
residue is poorly conserved with isoleucine and valine being 
the main variants. Our data are in stark contrast to the neutrali-
zation studies reported for AR3C (24, 64). AR3C neutralized 
27/29 E1E2 sequences tested in the HCVpp system (24, 64). 
Examination of the sequences showed that several isolates had 
either isoleucine or valine at position 438, thereby providing 
strong evidence that AR3C can still bind and neutralize these 
variants. If we adjust for this in our analysis, the level of conser-
vation is significantly improved, indeed, AR3C would be ranked 
16th overall.
The analysis of the bNAb epitope motifs shows that there is 
a strong preference for the bNAb epitope consensus sequence, 
there are very few variants circulating at significant levels. This 
makes it feasible to assess whether the major variants remain 
susceptible to neutralization. Indeed, only 30 variants would be 
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required to test this for the most conserved bNAbs as the epitopes 
have several residues in common.
A recent publication by Messina et  al. was the first to esti-
mate the relative prevalence of HCV globally (65). Prevalence 
was estimated in 20 geographical regions and by country, data 
permitting. Gt1 was the most prevalent in 15/20 geographical 
regions accounting for 46.2% of cases. Nearly one-third of cases 
worldwide are due to gt3. The remaining ~25% are due to gt2, gt4, 
and gt6. Of these, gt2 is the most widespread globally although 
it does not have the highest prevalence in any region. Gt4 is 
localized mainly to Africa, indeed, it has the highest frequency 
in North Africa and the Middle East and Central sub-Saharan 
Africa. Like gt2, gt6 is not the most prevalent genotype in any 
region; however, it is significant in East and Southeast Asia. 
Finally, gt5 accounts for the lowest frequency globally, but is 
highly localized in southern sub-Saharan Africa. Our data show 
that the top candidate bNAbs identified here should be effec-
tive against the majority of variants. Indeed, the HC84.20 and 
AR4A epitopes are conserved in >99% of available sequences 
for each genotype; therefore, a vaccine based on these epitopes 
would be predicted to be effective against all genotypes. While 
well-conserved against the most prevalent genotype, gt1, both 
1:7 and AP33 epitopes are less well conserved in gt3. However, 
in the case of 1:7, this was specifically gt3b sequences whereas 
AP33 epitope residues were more conserved in gt3b than gt3a 
suggesting that these antibodies may complement each other. In 
the same way, conservation of the AP33 epitope was reduced 
in gt2b and gt2c; however, the 1:7 epitope was highly conserved 
in these subtypes.
liMiTaTiOns
There are some caveats to the analysis reported in this study. 
The first is that our analysis is based on the publicly available 
sequence data available in Genbank. HCV sequence data in 
GenBank captures the known genomic diversity of this virus, 
and this dataset has for example underpinned the genotype 
and subtype definitions for the virus (4). HCV sequences may 
be submitted to GenBank as part of research projects with a 
wide variety of aims. Large sequence sets for a particular kind 
of research, for example, focusing on specific patient cohort 
types, may dominate. GenBank does not, therefore, accurately 
represent the range of HCV genomic diversity that a vaccine 
strategy would face “in the wild.” However, GenBank does 
provide a reasonable number of sequences within certain major 
genotypes and subtypes and so it does give a view on which 
genomic patterns are viable for the virus; which can, therefore, 
be presumed to exist in the wider epidemic. Another factor is 
that while the developed world has some coverage of the HCV 
glycoproteins, significant areas of the globe have little or no 
sequence data available. As a result, particular genotypes such 
as gt5 and gt6 are poorly represented, and it is possible that 
other circulating genotypes/subtypes have yet to be identified. 
To truly understand the extent to which a bNAb-based vaccine 
may be effective globally, this data gap should be addressed. 
The analysis also depends on the availability and quality of 
the bNAb epitope mapping data. Obviously, bNAbs that have 
not been finely mapped could not be included in our analysis. 
Although the number of co-crystallization studies has increased 
in recent years, the majority of epitope mapping is based on 
alanine-scanning mutagenesis. While this is an important tool, 
the results may also identify residues that prevent antibody-
interaction due to conformational changes. There are also 
examples whereby alanine-scanning experiments have not been 
able to conclusively identify the epitope, for instance, bNab e137 
where mutation of 15 different residues prevent antibody bind-
ing (46, 47, 66). This study is based on sequence conservation 
of bNAb epitopes, in practice, other factors including antibody 
affinity, epitope shielding by both the glycan shield, and HVR1 
will all influence the efficacy of each antibody. Furthermore, the 
epitope residues of many of the bNAbs have been determined by 
alanine-scanning mutagenesis, which does not unequivocally 
prove direct contact in the absence of structural information 
of the antigen/antibody complex. Unfortunately, the neutraliza-
tion data reported in the literature is also variable for the dif-
ferent bNAbs, the assays have not been standardized and few 
comparative studies are available.
Despite the limitations, from our study, we can conclude that 
based on epitope conservation and the available neutralization 
data that the most promising bNAbs for potential vaccine leads 
are HC84.20, AR4A, 1:7, A8, and AP33. Our results are encourag-
ing as several bNAb epitopes were highly conserved across all 
genotypes. This finding supports the notion that a single HCV 
vaccine could indeed fit all, and that ultimately tailoring vaccines 
to specific regions may prove to be unnecessary. However, further 
analysis of how the bNAbs perform in large-scale neutralization 
trials will be required to conclusively test this. Our analysis of the 
most prevalent epitope variants in circulation should provide use-
ful information when designing these experiments. Nonetheless 
to counter escape mutations and provide sterilizing immunity, 
it is likely to be desirable to develop a multi-target vaccine, this 
could be a B-cell and T-cell-based combination or a combination 
of different B-cell targets.
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